These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 16469003)
21. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135 [TBL] [Abstract][Full Text] [Related]
23. The natural history of benign prostatic hyperplasia. Fitzpatrick JM BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045 [TBL] [Abstract][Full Text] [Related]
24. [Drugs for prostatic adenoma]. Portet-Brunet L Soins; 1995 Oct; (599):69-70. PubMed ID: 8701357 [No Abstract] [Full Text] [Related]
25. [Medical therapy of benign prostatic hyperplasia]. Altarac S Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940 [TBL] [Abstract][Full Text] [Related]
26. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. Fine SR; Ginsberg P J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026 [TBL] [Abstract][Full Text] [Related]
27. The impact of alpha1-adrenoceptors on prostate cancer growth. Stamatiou K; Skolarikos A; Sofras F Urology; 2008 Apr; 71(4):756-7. PubMed ID: 18291511 [No Abstract] [Full Text] [Related]
28. [The experience in postoperative administration of alpha-adrenoblockers]. Miller AM Urologiia; 2007; (5):55-8. PubMed ID: 18254227 [TBL] [Abstract][Full Text] [Related]
29. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766 [TBL] [Abstract][Full Text] [Related]
30. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M; BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317 [TBL] [Abstract][Full Text] [Related]
31. Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. Hansen BJ J Urol; 1996 Jul; 156(1):184-5. PubMed ID: 8648797 [No Abstract] [Full Text] [Related]
33. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? Carson CC BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053 [TBL] [Abstract][Full Text] [Related]
34. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. Roehrborn CG BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681 [TBL] [Abstract][Full Text] [Related]
35. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Resnick MI; Roehrborn CG Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442 [TBL] [Abstract][Full Text] [Related]